Literature DB >> 18653764

Allele-specific silencing of the dominant disease allele in sialuria by RNA interference.

Riko D Klootwijk1, Paul J M Savelkoul, Carla Ciccone, Irini Manoli, Natasha J Caplen, Donna M Krasnewich, William A Gahl, Marjan Huizing.   

Abstract

Dominant disease alleles are attractive therapeutic targets for allele-specific gene silencing by small interfering RNA (siRNA). Sialuria is a dominant disorder caused by missense mutations in the allosteric site of GNE, coding for the rate-limiting enzyme of sialic acid biosynthesis, UDP-GlcNAc 2-epimerase/ManNAc kinase. The resultant loss of feedback inhibition of GNE-epimerase activity by CMP-sialic acid causes excessive production of free sialic acid. For this study we employed synthetic siRNAs specifically targeting the dominant GNE mutation c.797G>A (p.R266Q) in sialuria fibroblasts. We demonstrated successful siRNA-mediated down-regulation of the mutant allele by allele-specific real-time PCR. Importantly, mutant allele-specific silencing resulted in a significant decrease of free sialic acid, to within the normal range. Feedback inhibition of GNE-epimerase activity by CMP-sialic acid recovered after silencing demonstrating specificity of this effect. These findings indicate that allele-specific silencing of a mutated allele is a viable therapeutic strategy for autosomal dominant diseases, including sialuria.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18653764      PMCID: PMC2574030          DOI: 10.1096/fj.08-110890

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  40 in total

Review 1.  Allele-specific RNA interference for neurological disease.

Authors:  E Rodriguez-Lebron; H L Paulson
Journal:  Gene Ther       Date:  2006-03       Impact factor: 5.250

2.  Intrastriatal rAAV-mediated delivery of anti-huntingtin shRNAs induces partial reversal of disease progression in R6/1 Huntington's disease transgenic mice.

Authors:  Edgardo Rodriguez-Lebron; Eileen M Denovan-Wright; Kevin Nash; Alfred S Lewin; Ronald J Mandel
Journal:  Mol Ther       Date:  2005-10       Impact factor: 11.454

3.  Therapeutic RNA interference of malignant melanoma by electrotransfer of small interfering RNA targeting Mitf.

Authors:  N Nakai; T Kishida; M Shin-Ya; J Imanishi; Y Ueda; S Kishimoto; O Mazda
Journal:  Gene Ther       Date:  2006-10-05       Impact factor: 5.250

4.  Silencing primary dystonia: lentiviral-mediated RNA interference therapy for DYT1 dystonia.

Authors:  Pedro Gonzalez-Alegre; Nicole Bode; Beverly L Davidson; Henry L Paulson
Journal:  J Neurosci       Date:  2005-11-09       Impact factor: 6.167

5.  Mutations in the human UDP-N-acetylglucosamine 2-epimerase gene define the disease sialuria and the allosteric site of the enzyme.

Authors:  R Seppala; V P Lehto; W A Gahl
Journal:  Am J Hum Genet       Date:  1999-06       Impact factor: 11.025

6.  Allele-specific RNAi selectively silences mutant SOD1 and achieves significant therapeutic benefit in vivo.

Authors:  Xugang Xia; Hongxia Zhou; Yong Huang; Zuoshang Xu
Journal:  Neurobiol Dis       Date:  2006-07-20       Impact factor: 5.996

7.  Transgenic small interfering RNA halts amyotrophic lateral sclerosis in a mouse model.

Authors:  Yuki Saito; Takanori Yokota; Tasuku Mitani; Kaoru Ito; Masayuki Anzai; Makoto Miyagishi; Kazunari Taira; Hidehiro Mizusawa
Journal:  J Biol Chem       Date:  2005-10-12       Impact factor: 5.157

8.  Use of a cell-free system to determine UDP-N-acetylglucosamine 2-epimerase and N-acetylmannosamine kinase activities in human hereditary inclusion body myopathy.

Authors:  Susan E Sparks; Carla Ciccone; Molly Lalor; Eduard Orvisky; Riko Klootwijk; Paul J Savelkoul; Marinos C Dalakas; Donna M Krasnewich; William A Gahl; Marjan Huizing
Journal:  Glycobiology       Date:  2005-06-29       Impact factor: 4.313

9.  Towards mutation-independent silencing of genes involved in retinal degeneration by RNA interference.

Authors:  S M Cashman; E A Binkley; R Kumar-Singh
Journal:  Gene Ther       Date:  2005-08       Impact factor: 5.250

Review 10.  Clinical spectrum of infantile free sialic acid storage disease.

Authors:  E Lemyre; P Russo; S B Melançon; R Gagné; M Potier; M Lambert
Journal:  Am J Med Genet       Date:  1999-02-19
View more
  6 in total

Review 1.  Research progress in allele-specific expression and its regulatory mechanisms.

Authors:  Uma Gaur; Kui Li; Shuqi Mei; Guisheng Liu
Journal:  J Appl Genet       Date:  2013-04-23       Impact factor: 3.240

2.  Allele-specific siRNA knockdown as a personalized treatment strategy for vascular Ehlers-Danlos syndrome in human fibroblasts.

Authors:  Gerd A Müller; Uwe Hansen; Zhi Xu; Benjamin Griswold; Mark I Talan; Nazli B McDonnell; Wilfried Briest
Journal:  FASEB J       Date:  2011-10-28       Impact factor: 5.191

Review 3.  UDP-GlcNAc 2-Epimerase/ManNAc Kinase (GNE): A Master Regulator of Sialic Acid Synthesis.

Authors:  Stephan Hinderlich; Wenke Weidemann; Tal Yardeni; Rüdiger Horstkorte; Marjan Huizing
Journal:  Top Curr Chem       Date:  2015

4.  Profiling of mismatch discrimination in RNAi enabled rational design of allele-specific siRNAs.

Authors:  Huang Huang; Renping Qiao; Deyao Zhao; Tong Zhang; Youxian Li; Fan Yi; Fangfang Lai; Junmei Hong; Xianfeng Ding; Zhenjun Yang; Lihe Zhang; Quan Du; Zicai Liang
Journal:  Nucleic Acids Res       Date:  2009-12       Impact factor: 16.971

5.  Allele-specific Col1a1 silencing reduces mutant collagen in fibroblasts from Brtl mouse, a model for classical osteogenesis imperfecta.

Authors:  Julie Rousseau; Roberta Gioia; Pierre Layrolle; Blandine Lieubeau; Dominique Heymann; Antonio Rossi; Joan C Marini; Valerie Trichet; Antonella Forlino
Journal:  Eur J Hum Genet       Date:  2013-09-11       Impact factor: 4.246

6.  Allele-specific silencing therapy for Dynamin 2-related dominant centronuclear myopathy.

Authors:  Delphine Trochet; Bernard Prudhon; Maud Beuvin; Cécile Peccate; Stéphanie Lorain; Laura Julien; Sofia Benkhelifa-Ziyyat; Aymen Rabai; Kamel Mamchaoui; Arnaud Ferry; Jocelyn Laporte; Pascale Guicheney; Stéphane Vassilopoulos; Marc Bitoun
Journal:  EMBO Mol Med       Date:  2018-02       Impact factor: 12.137

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.